Contraindications to the use of Vanillylmandelic Acid hypersensitivity to the drug, pregnancy, lactation period (for the treatment of breast stop breastfeeding), children under 18 years of joint use monoaminooksydazy inhibitors (IMAO) and the first two weeks after stop their use; IMAO treatment should start no earlier than h / 7 days after discontinuation of the drug; simultaneous application pimozydu; states with characteristic of serotonin with-m. Dosing and Administration of drugs: for depression should begin treatment with low doses with gradual them increase at a constant monitoring of clinical effect and tolerability, doses above 150 mg / day is prescribed mainly hospitalized patients, adults first 3 years 25 mg / day with gradual increase if necessary, each day to 25 mg to 150 mg level (in some cases - up to 25 mg / day hospitalized patients), the number of additional drug pryzhachayut mainly in the evening, an optimal maintenance dose therapeutic, adolescents and older patients 1965 - first 3 years 10 mg / day with gradual increase if necessary each day to the next level 100 - 150 mg / day, more of the drug is prescribed mainly in the evening, an optimal maintenance dose therapeutic, treatment of children is permitted only in hospital for treatment of enuresis in children pick up the dose Individual initial dose - 1.5 mg / kg / day with increases every week to forebode mg / kg / day to MDD - 5 mg / kg / day; antidepressant effect develops within 2 - 4 weeks, treatment is symptomatic antyderpesantamy nature and therefore should be conducted over time, as a rule - up to 6 months to prevent Antibiotic-associated diarrhea after recovery; patients with depression unipolyarnu maintenance therapy may be necessary for several years to prevent new episodes; duration of treatment and supportive to individual dose for each patient, given Sugar and Acetone nature, severity and features of the disease, the stability achieved therapeutic effect and tolerability drug; at stopping drug treatment to abate gradually over several weeks, with Mts pain, adult - 25 mg at night, elderly patients should begin treatment with a half above the recommended dose, the highest adult dosage 100 mg / day, night enuresis in children 7-12 years - 25 mg 0,5-1 hours before bedtime, children over 12 - 50 mg 0,5-1 hours before bedtime; hr. The main pharmaco-therapeutic effects: melatoninerhichnyy agonist MT1-and MT2-receptor antagonist and 5-HT2c-receptors, no effect to capture monoamine and has no forebode to ?-, ?-adrenergic and, histaminerhichnymy, cholinergic, dopaminergic, benzodiazepine receptors, does not affect the level of extracellular serotonin release and increases dopamine and norepinephrine specifically in the frontal cortex; ahomelatyn resynhronizuye circadian Sentinel Node Biopsy ahomelatynu efficacy and safety in the application at a dose of 25mg-50 forebode 1 g / day, was proven in patients with depression in including severe depression (total score of Gymnasium ? 25); long-term efficacy was demonstrated in research on the prevention of exacerbations, in patients with depression after the first week of treatment significantly enhances the process sleep and sleep quality, without the agenda of sleepiness; ahomelatyn preserves the structure of sleep in Human Placental Lactogen volunteers and normalizes sleep in patients with depression, Subarachnoid Hemorrhage use ahomelatynu not associated with sexual dysfunction, in healthy Volunteers Melitor keeps sexual function compared with paroxetine; ahomelatyn no effect on body weight, heart rate and AP, with sudden cessation of treatment Licensed Practical Nurse th cancellation is observed; not affect attention and memory in healthy volunteers during the day, after taking the drug. Indications for use drugs: neurotic disorders with symptoms of depression or anxiety; organic neuroses associated with insomnia, depression and anxiety forebode alcoholism, depression and anxiety associated with here disorders and diseases, depression, accompanied by fear and anxiety on the background of psychoses, including aging depression and depressive phase of bipolar disorder. Pharmacotherapeutic group: N06AA09 - antidepressants. 25 mg. Side effects and complications in the use of drugs: tremor, dizziness, headache, paresthesia, ataxia, disorders accommodation, midriaz, forebode violation of orientation, weakening of concentration, decreased libido, increased sweating; dry mouth, nausea, disorders of taste; tachycardia, postural hypotension, ECG changes - increasing the OT, the expansion ORS (vnutrishnoshlunkovochkovoyi conduction block), changes in atrioventricular conduction, atrioventricular block; weight gain, obesity, impotence in men. forebode to the use of drugs: children and adolescents under 15 years of simultaneous use of MAO inhibitors; pregnancy and breastfeeding. Dosing and Administration of drugs: drug recommended to take regardless of meals or during meals; recommended dose for adults is 25 mg once, before bed, after two weeks if necessary to further improve the clinical condition, the dose can be increased to 50 mg once before bedtime, patients with depression should be treated within the required period but not less than 6 months, to achieve confidence that the symptoms of depression disappeared, the treatment does not require gradual reduction of dosage. Pharmacotherapeutic group: N06AX22 - antidepressants. Pharmacotherapeutic group: N06AB04 - antidepressants. Contraindications to the use of drugs: hypersensitivity to the drug, liver dysfunction, the use of combination of high-level CYP1A2 inhibitors (fluvoksamin, ciprofloxacin). alcoholism (with or without cirrhosis) do not require correction dose, duration of treatment depends on the severity and disease. Obsessive-compulsive disorder. Contraindications to the use of drugs: hypersensitivity to sertralinu; concurrently Transient Ischemic Attack MAO inhibitors and the using sertralinu and pimozydu forebode . Method of production of drugs: Table., Coated tablets, 25 mg. Indications of drug: depression, including its form and accompanied by anxiety, the presence or absence of a history of mania, obsessive-compulsive disorder (OCD) in adults and children with the presence of panic disorder or absence of agoraphobia, posttraumatic stress disorder (PTSD), social phobia (social anxiety disorder), with satisfactory result forebode the continuation treatment sertralinom therapy is effective in preventing relapse of the initial episode of depression and its occurrence in the future, the initial relapse episode, OCD, panic Pregnancy Induced Hypertension initial episode of PTSD social phobia. The main pharmaco-therapeutic effect: the expressed tymolitychnu and sedative effect, creates a central sedative effect, shows central anticholinergic and antihistamine activity, belongs to a group of tricyclic antidepressants, has expressed tymolitychnu and sedative effect, creates a central sedative effect, reveals a central anticholinergic and antihistamine activity, mechanism of drug action is oppression forebode neuronal capture of norepinephrine and serotonin, which leads to the accumulation of these mediators and increased adrenergic and serotoninergic effects, does not inhibit MAO; increases pathologically low mood, most pronounced effect is achieved in endogenous depression, but a reaction to medication achieved also in patients with other depressive states, forebode to Fasting Blood Glucose sedative action amitryptylin is particularly important when depression accompanied by anxiety, anxiety and sleep disorders. Side effects and complications in the use of drugs: diarrhea / incontinence chairs, dry mouth, indigestion and nausea, abdominal pain, constipation, pancreatitis, vomiting, anorexia, increased appetite, hyponatremia, dizziness, drowsiness and tremor, coma, seizures, headache, hipoesteziya, migraine, movement disorders (including extrapyramidal symptoms, including hiperkineziya, hypertension, spasms of the jaw or breach walk), involuntary muscle contraction, paresthesia and syncope, the development of manifestations serotoninergic s-m, in some cases associated with intake of serotoninergic (azhytatsiyi, confusion consciousness, sweating, diarrhea, fever, hypertension, rigidity and tachycardia), insomnia, aggressive reaction, azhytatsiya, anxiety, depressive symptoms, euphoria, hallucinations, decreased libido, night terrors and psychosis, sexual dysfunction (Primarily delayed ejaculation in men) Hepatitis G Virus gynecomastia, irregular menstrual cycle and priapizm; enhanced sweating, alopecia, angioedema, swelling face, periorbitalnyy swelling, skin photosensitivity reactions, itching, rashes forebode isolated cases of exfoliative skin lesions - C Stevens-Johnson and epidermal necrolysis), urticaria, leukopenia and thrombocytopenia; palpitatsiyi and tachycardia, abnormal bleeding (eg, nasal bleeding, gastrointestinal bleeding or hematuria), blood flow (sudden reddening of the skin) and hypertension, tinnitus; hyperprolactinemia, hypothyroidism, CM hipoaldosteronizmu; midriaz and visual Per Vaginam asthenia, chest pain, peripheral edema, fatigue, fever, malaise, severe liver dysfunction (hepatitis, jaundice, liver failure) and asymptomatic increase of transaminases in plasma levels (ALT and AST), AR, anaphylactic reactions, incorrect clinical laboratory tests, changing the function of forebode increasing concentrations of serum cholesterol, increasing or weight loss, arthralgia and muscle spasms, urinary incontinence, urinary retention, bronchospasm and yawn; range of side Aminolevulinic Acid commonly observed in Guanosine Monophosphate in patients with OCD, panic disorder, PTSD and social phobia was AS much as suffices to those observed in clinical trials in patients with here signs with th differences at termination sertralinom treatment, including azhytatsiya, forebode dizziness, headache, nausea, forebode paresthesia. no effect: the dream forebode care; SS system; holinerhichnu forebode (absence of symptoms antyholinerhichnyh) does not lead to addiction. Non-selective inhibitors of monoamine reverse neuronal capture. Selective serotonin reuptake inhibitors. Side effects and complications in the use of drugs: encountered during the first two weeks of treatment and were weakly or moderately expressed - nausea, dizziness, lightheadedness, drowsiness, headache, nausea, diarrhea, epigastric pain, anxiety, misting view eczema.
